VRCA Q2 2025 Earnings — Verrica Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

VRCAVerrica Pharmaceuticals Inc.

$56M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$13M+145.4% YoY

Gross Profit

$12M97.3% margin

Operating Income

$2M11.9% margin

Net Income

$204,0001.6% margin

EPS (Diluted)

$0.02

QoQ Revenue Growth

+269.4%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$10M

Stock-Based Comp.

$888,000

Balance Sheet

Total Assets

$39M

Total Liabilities

$57M

Stockholders' Equity

-$17M

Cash & Equivalents

$15M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$13M	$5M	+145.4%
Gross Profit	$12M	$5M	+166.7%
Operating Income	$2M	-$15M	+109.9%
Net Income	$204,000	-$17M	+101.2%

Revenue Segments

License And Collaboration Revenue

$8M64%

Product

$5M36%